GLP-1 Care — Doctor + Coach + Protocols app | Kokorology
One monthly plan for GLP-1 users (Ozempic, Mounjaro, Wegovy, Zepbound). Doctor intake, monthly 1:1 with Sabin, weekly digital check-ins, bi-monthly doctor reviews, and the Protocols app with the GLP-1 protocol preloaded. €395 today, then €245/mo — founding price locked.
What's included
Every Kokorology Care package is one monthly plan: a monthly 1:1 with Sabin, weekly digital check-ins, and the Protocols app preloaded with the anchor-specific protocol. GLP-1 and taper packages add clinician intake and bi-monthly medical reviews. You keep your own doctor; we coach around them.
Who it's for
Adults already inside the protocol — on the peptide, mid-taper, mid-cycle, or working an anchor daily — who want structured coaching, not a course. Founders, operators, clinicians, athletes, and knowledge workers whose capacity to stay regulated is the whole job.
How it works
You book, complete the coaching onboarding, and land on a first 1:1 within seven days. Between sessions, weekly check-ins flag drift (sleep debt, HRV drop, protein floor missed, cortisol curve inverted) and route it to the next call. Cancel any time; keep your purchased Anchors.
Related
See the full Care package index, the Anchor protocols that each package coaches, or start with the 7-Day Reset.
What the evidence actually supports
Evidence reviewed: 2026-11-16
Semaglutide & Tirzepatide
These medicines have substantial human evidence for defined metabolic indications. Approval belongs to a product, indication and country—not to every vial bearing the molecule's name. Appetite effects are not proof of nervous-system regulation or dorsal-vagal shutdown.
Protect nutrition, strength and hydration with an individual plan. An Anchor, supplement bundle or fixed fasting window is not a medical prerequisite. Obesity treatment may be long term; stopping commonly leads to regain, and a taper is not proven to prevent it. Do not change prescribed treatment based on wearable readiness alone.
- EMA: Wegovy product information
- EMA: Mounjaro product information
- FDA: concerns with unapproved GLP-1 drugs
Pills, new pens and the metabolic pipeline
Oral Wegovy (semaglutide 25 mg) was approved in the US in December 2025 and in the EU on 15 July 2026; in OASIS 4 (307 adults without diabetes) mean weight change at 64 weeks was −13.6% versus −2.2% with placebo. On 1 April 2026 FDA approved Foundayo (orforglipron), the first once-daily GLP-1 pill without food or water timing rules; worth knowing that orforglipron is a small molecule, not a peptide at all. Wegovy injection also holds a US accelerated MASH indication (August 2025) for noncirrhotic disease with F2–F3 fibrosis; that is not a liver-detox or longevity claim.
A pill changes the route, not the biology: appetite still drops, so protein, strength training and hydration still decide what the lost weight is made of. Approval belongs to a product, indication and country; EU authorisation of oral Wegovy does not confirm Portuguese supply or reimbursement, and Foundayo's approval verified here is US-only.
- FDA: oral Wegovy approval letter
- OASIS 4 (2025): oral semaglutide
- EMA, May 2026: first oral GLP-1 for weight management
- FDA, 1 Apr 2026: Foundayo (orforglipron) approval
- FDA: Wegovy MASH accelerated approval
Semaglutide: the eye-safety update
On 6 June 2025, EMA concluded that NAION, an optic-nerve condition, is a very rare adverse effect of semaglutide. Observational estimates in adults with type 2 diabetes corresponded to about one additional case per 10,000 person-years; that estimate is not a risk calculation for every individual.
Sudden vision loss or rapidly worsening eyesight requires urgent medical assessment. This warning is specific to semaglutide, not established as an identical risk for all peptides or incretin medicines. The clinician handles treatment decisions.

